| 2.09 -0.01 (-0.48%) | 03-22 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Recro Pharma, Inc. operates as a contract development and manufacturing organization (CDMO), offering comprehensive services for the development, production, and packaging of diverse therapeutic dosage forms. The company primarily specializes in small molecule therapeutic development, serving both domestic U.S. and international clients. Its extensive capabilities encompass a wide array of formats, including oral solid doses, sterile injectable solutions, oral liquid preparations, tablets, topical formulations, liquid/powder-filled capsules, ophthalmic droppers, liposomal products, and nano/microparticles. Furthermore, Recro Pharma provides specialized services such as aseptic fill/finish, lyophilization (freeze-drying), final packaging, and logistics management. Originally founded as Recro Pharma I, Inc., the company underwent a name change to Recro Pharma, Inc. in August 2008. The organization was established in 2007 and is headquartered in Exton, Pennsylvania.
Wed, 21 Sep 2022
A New Pain Treatment Requires Accurate And Reliable Data - Clinical Leader
Mon, 21 Mar 2022
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation - GlobeNewswire
Fri, 13 Aug 2021
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO - GlobeNewswire
Wed, 16 Jun 2021
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors - citybiz
Thu, 21 Nov 2019
Recro Pharma completes split into two companies - The Business Journals
Thu, 22 Aug 2019
The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrop - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|